Medite Cancer Diagnostics, Inc.
Medite Cancer Diagnostics, Inc.
Your view on MDIT
Overview
What the company does, where it operates, and who runs it.
About Medite Cancer Diagnostics, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Jeffrey Rencher
- Headquarters
- 10524 Moss Park Road, Orlando, FL, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Jeffrey Rencher
- Headquarters
- 10524 Moss Park Road, Orlando, FL, US
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases.
The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning.
It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers.
In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa.
The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Medite Cancer Diagnostics, Inc., and the rating behind it. MDIT last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Medite Cancer Diagnostics, Inc.. Starting points for Medite Cancer Diagnostics, Inc.: EPS -$0.26, beta -37.15 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Medite Cancer Diagnostics, Inc.. Medite Cancer Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Medite Cancer Diagnostics, Inc.. Trailing twelve-month EPS for Medite Cancer Diagnostics, Inc. stands at -$0.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Medite Cancer Diagnostics, Inc.. Medite Cancer Diagnostics, Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Medite Cancer Diagnostics, Inc. valued side by side against its closest peers. Medite Cancer Diagnostics, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Medite Cancer Diagnostics, Inc., and how their positions are changing. At a $8,672 market value, institutional positions materially move Medite Cancer Diagnostics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Medite Cancer Diagnostics, Inc. executives and directors. Shares of Medite Cancer Diagnostics, Inc. have traded between $0.0001 and $0.0050 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Medite Cancer Diagnostics, Inc.. Medite Cancer Diagnostics, Inc. is a $8,672 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Medite Cancer Diagnostics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Medite Cancer Diagnostics, Inc.. Coverage tracks Medite Cancer Diagnostics, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.